What is Cure HHT?
Cure HHT operates as a specialized nonprofit organization focused on the complex challenges of Hereditary Hemorrhagic Telangiectasia, a genetic blood vessel disorder impacting approximately 1 in 5,000 individuals. The organization serves as a central hub for the HHT community, providing essential treatment guidelines, robust support networks, and comprehensive educational resources for patients and medical professionals alike. By bridging the gap between clinical research and patient advocacy, Cure HHT maintains a unique market position as the primary authority on HHT-related health outcomes and diagnostic improvements. Their operational model emphasizes the synthesis of scientific inquiry with community-driven support, effectively mobilizing resources to address the systemic needs of those affected by this chronic condition.
How much funding has Cure HHT raised?
Cure HHT has raised a total of $116K across 1 funding round:
Debt
$116K
Debt (2021): $116K with participation from PPP
Key Investors in Cure HHT
PPP
Public-Private Partnership
What's next for Cure HHT?
With the recent influx of capital, Cure HHT is poised to transition into a more aggressive phase of research development and clinical outreach. The organization will likely prioritize the expansion of its treatment guidelines and the enhancement of its digital support infrastructure to reach a broader global patient base. Strategic focus will remain on fostering partnerships with academic institutions and pharmaceutical entities to expedite the discovery of therapeutic interventions. As the organization matures, the emphasis will shift toward long-term sustainability and the solidification of its role as the definitive voice in HHT advocacy, ensuring that the momentum generated by this latest financing round translates into tangible improvements in patient quality of life and diagnostic accuracy.
See full Cure HHT company page
